Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) Shares Outstanding (Diluted Average) (2021 - 2025)

Cyclerion Therapeutics (CYCN) has 5 years of Shares Outstanding (Diluted Average) data on record, last reported at $3.0 million in Q3 2025.

  • For Q3 2025, Shares Outstanding (Diluted Average) rose 17.62% year-over-year to $3.0 million; the TTM value through Sep 2025 reached $3.0 million, up 17.62%, while the annual FY2024 figure was $2.5 million, 7.7% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $3.0 million in Q3 2025 per CYCN's latest filing, down from $3.1 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $39.1 million in Q4 2021 and bottomed at $43425.0 in Q1 2022.
  • Average Shares Outstanding (Diluted Average) over 5 years is $8.1 million, with a median of $2.5 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Diluted Average): crashed 94.45% in 2022, then soared 4910.94% in 2023.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $39.1 million in 2021, then plummeted by 94.45% to $2.2 million in 2022, then increased by 7.59% to $2.3 million in 2023, then increased by 7.7% to $2.5 million in 2024, then grew by 17.99% to $3.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Diluted Average) were $3.0 million in Q3 2025, $3.1 million in Q2 2025, and $2.6 million in Q1 2025.